Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention: Findings From the ADAPT-DES Study.
暂无分享,去创建一个
G. Stone | A. Kirtane | G. Weisz | R. Mehran | M. Rinaldi | B. Brodie | T. Stuckey | B. Witzenbichler | A. Crowley | O. Ben‐Yehuda | D. Metzger | Rajesh Gupta | Yangbo Liu | O. Ben-Yehuda | Aaron Crowley
[1] T. Bergmeijer,et al. The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions , 2017, Journal of thrombosis and haemostasis : JTH.
[2] Yun Gi Kim,et al. Cigarette Smoking Does Not Enhance Clopidogrel Responsiveness After Adjusting VerifyNow P2Y12 Reaction Unit for the Influence of Hemoglobin Level. , 2016, JACC. Cardiovascular interventions.
[3] D. Sibbing,et al. Smoking and Clopidogrel Response Revisited: Hemoglobin Levels Explaining the Smoker's Paradox. , 2016, JACC. Cardiovascular interventions.
[4] Deepak L. Bhatt,et al. Smoker's Paradox in Patients With ST‐Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention , 2016, Journal of the American Heart Association.
[5] Yun Gi Kim,et al. Different Influences of Hematocrit on the Results of Two Point-Of-Care Platelet Function Tests, the VerifyNow Assay and Multiple Electrode Platelet Aggregometry , 2014, PloS one.
[6] D. Prabhakaran,et al. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. , 2014, American heart journal.
[7] J. Rade,et al. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness , 2013, Journal of thrombosis and haemostasis : JTH.
[8] Peter L Duffy,et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.
[9] T. Nolin,et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. , 2013, Journal of the American College of Cardiology.
[10] Si‐Hyuck Kang,et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of ‘smokers’ paradox' , 2012, Heart.
[11] L. Wallentin,et al. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2012, American heart journal.
[12] Hae-Young Lee,et al. Enhanced Clopidogrel Responsiveness in Smokers: Smokers' Paradox Is Dependent on Cytochrome P450 CYP1A2 Status , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[13] B. Baker,et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. , 2008, Journal of the American College of Cardiology.
[14] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[15] J. J. Griffin,et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. , 2005, American heart journal.
[16] I. Ockene,et al. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. , 1997, Circulation.
[17] M. Ishihara,et al. Clinical implications of cigarette smoking in acute myocardial infarction: acute angiographic findings and long-term prognosis. , 1997, American heart journal.
[18] D. Nordenberg,et al. The effect of cigarette smoking on hemoglobin levels and anemia screening. , 1990, JAMA.
[19] E. Gilpin,et al. Smoking status at the time of acute myocardial infarction and subsequent prognosis. , 1985, American heart journal.